25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Gempharmatech Co. Ltd. A
Buy, Hold or Sell?

Let's analyze Gempharmatech together

I guess you are interested in Gempharmatech Co. Ltd. A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Gempharmatech Co. Ltd. A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Gempharmatech Co. Ltd. A

I send you an email if I find something interesting about Gempharmatech Co. Ltd. A.

1. Quick Overview

1.1. Quick analysis of Gempharmatech (30 sec.)










1.2. What can you expect buying and holding a share of Gempharmatech? (30 sec.)

How much money do you get?

How much money do you get?
¥0.02
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥5.18
Expected worth in 1 year
¥5.28
How sure are you?
90.9%

+ What do you gain per year?

Total Gains per Share
¥0.26
Return On Investment
1.9%

For what price can you sell your share?

Current Price per Share
¥13.95
Expected price per share
¥12.04 - ¥16.16
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Gempharmatech (5 min.)




Live pricePrice per Share (EOD)
¥13.95

2.2. Growth of Gempharmatech (5 min.)




Is Gempharmatech growing?

Current yearPrevious yearGrowGrow %
How rich?$291.9m$278.9m$13m4.5%

How much money is Gempharmatech making?

Current yearPrevious yearGrowGrow %
Making money$4.7m$5.3m-$509.3k-10.6%
Net Profit Margin20.5%26.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Gempharmatech (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Gempharmatech?

Welcome investor! Gempharmatech's management wants to use your money to grow the business. In return you get a share of Gempharmatech.

First you should know what it really means to hold a share of Gempharmatech. And how you can make/lose money.

Speculation

The Price per Share of Gempharmatech is ¥13.95. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Gempharmatech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Gempharmatech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥5.18. Based on the TTM, the Book Value Change Per Share is ¥0.02 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.04 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Gempharmatech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.1%0.010.1%0.010.1%0.010.1%0.010.1%
Usd Book Value Change Per Share0.000.0%0.000.0%0.010.1%0.060.5%0.060.5%
Usd Dividend Per Share0.020.2%0.010.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.030.2%0.010.1%0.010.1%0.070.5%0.070.5%
Usd Price Per Share2.03-1.99-2.92-2.53-2.53-
Price to Earnings Ratio69.30-46.62-58.67-49.64-49.64-
Price-to-Total Gains Ratio79.60-195.57-234.03-199.17-199.17-
Price to Book Ratio2.86-2.80-4.31-3.74-3.74-
Price-to-Total Gains Ratio79.60-195.57-234.03-199.17-199.17-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.918125
Number of shares521
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share0.000.06
Usd Total Gains Per Share0.010.07
Gains per Quarter (521 shares)4.7335.08
Gains per Year (521 shares)18.90140.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
112795135130
224142811270270
336214716405410
447286622540550
559358527675690
6714210433809830
7834912338944970
895571424310791110
9107641614912141250
10118711805413491390

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%10.01.00.090.9%10.01.00.090.9%10.01.00.090.9%10.01.00.090.9%
Dividend per Share4.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%11.00.00.0100.0%
Total Gains per Share3.01.00.075.0%10.01.00.090.9%10.01.00.090.9%10.01.00.090.9%10.01.00.090.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Gempharmatech Co. Ltd. A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0250.025+0%0.087-72%0.471-95%0.471-95%
Book Value Per Share--5.1795.178+0%4.948+5%4.713+10%4.713+10%
Current Ratio--4.9144.591+7%6.233-21%5.618-13%5.618-13%
Debt To Asset Ratio--0.1620.174-7%0.141+15%0.157+3%0.157+3%
Debt To Equity Ratio--0.1930.211-8%0.165+17%0.188+3%0.188+3%
Dividend Per Share--0.1610.041+290%0.011+1416%0.019+750%0.019+750%
Enterprise Value--5653673703.9705498962548.873+3%8381141227.650-33%7933348397.111-29%7933348397.111-29%
Eps--0.0530.085-37%0.094-43%0.094-43%0.094-43%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--8.3478.184+2%14.587-43%13.515-38%13.515-38%
Free Cash Flow Per Share--0.025-0.061+348%-0.070+385%-0.062+352%-0.062+352%
Free Cash Flow To Equity Per Share--0.025-0.061+348%-0.070+385%-0.062+352%-0.062+352%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Market Cap5719500000.000-6%6063900000.0005947050000.000+2%8716600000.000-30%7546236363.636-20%7546236363.636-20%
Net Profit Margin--0.1290.205-37%0.263-51%0.260-50%0.260-50%
Operating Margin----0%-0%-0%-0%
Operating Ratio--1.2321.144+8%1.041+18%1.044+18%1.044+18%
Pb Ratio2.694-6%2.8562.800+2%4.310-34%3.740-24%3.740-24%
Pe Ratio65.361-6%69.29646.624+49%58.673+18%49.644+40%49.644+40%
Price Per Share13.950-6%14.79014.505+2%21.260-30%18.405-20%18.405-20%
Price To Free Cash Flow Ratio141.097-6%149.594106.817+40%-83.322+156%14.653+921%14.653+921%
Price To Total Gains Ratio75.076-6%79.597195.573-59%234.028-66%199.173-60%199.173-60%
Quick Ratio--2.7632.405+15%3.697-25%3.343-17%3.343-17%
Return On Assets--0.0090.014-36%0.016-47%0.018-51%0.018-51%
Return On Equity--0.0100.016-37%0.019-46%0.021-51%0.021-51%
Total Gains Per Share--0.1860.066+182%0.097+91%0.490-62%0.490-62%
Usd Book Value--291955701.143291926211.203+0%278923569.050+5%265706233.066+10%265706233.066+10%
Usd Book Value Change Per Share--0.0030.003+0%0.012-72%0.065-95%0.065-95%
Usd Book Value Per Share--0.7120.712+0%0.680+5%0.648+10%0.648+10%
Usd Dividend Per Share--0.0220.006+290%0.001+1416%0.003+750%0.003+750%
Usd Enterprise Value--777380134.296756107350.470+3%1152406918.802-33%1090835404.603-29%1090835404.603-29%
Usd Eps--0.0070.012-37%0.013-43%0.013-43%0.013-43%
Usd Free Cash Flow--1393418.225-3456706.390+348%-3970666.707+385%-3505681.375+352%-3505681.375+352%
Usd Free Cash Flow Per Share--0.003-0.008+348%-0.010+385%-0.009+352%-0.009+352%
Usd Free Cash Flow To Equity Per Share--0.003-0.008+348%-0.010+385%-0.009+352%-0.009+352%
Usd Market Cap786431250.000-6%833786250.000817719375.000+2%1198532500.000-30%1037607500.000-20%1037607500.000-20%
Usd Price Per Share1.918-6%2.0341.994+2%2.923-30%2.531-20%2.531-20%
Usd Profit--3008040.8824792371.196-37%5301708.359-43%5272150.949-43%5272150.949-43%
Usd Revenue--23283594.74423283587.642+0%20103554.265+16%20605659.812+13%20605659.812+13%
Usd Total Gains Per Share--0.0260.009+182%0.013+91%0.067-62%0.067-62%
 EOD+4 -4MRQTTM+25 -12YOY+15 -225Y+13 -2410Y+13 -24

3.3 Fundamental Score

Let's check the fundamental score of Gempharmatech Co. Ltd. A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1565.361
Price to Book Ratio (EOD)Between0-12.694
Net Profit Margin (MRQ)Greater than00.129
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.763
Current Ratio (MRQ)Greater than14.914
Debt to Asset Ratio (MRQ)Less than10.162
Debt to Equity Ratio (MRQ)Less than10.193
Return on Equity (MRQ)Greater than0.150.010
Return on Assets (MRQ)Greater than0.050.009
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Gempharmatech Co. Ltd. A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.563
Ma 20Greater thanMa 5013.066
Ma 50Greater thanMa 10013.519
Ma 100Greater thanMa 20013.166
OpenGreater thanClose13.390
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Gempharmatech Co. Ltd. A

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services. The company was founded in 2017 and is headquartered in Nanjing, China.

Fundamental data was last updated by Penke on 2025-02-02 12:14:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Gempharmatech earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Gempharmatech to the Biotechnology industry mean.
  • A Net Profit Margin of 12.9% means that ¥0.13 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 12.9%. The company is making a huge profit. +2
  • The TTM is 20.5%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ12.9%TTM20.5%-7.5%
TTM20.5%YOY26.3%-5.9%
TTM20.5%5Y26.0%-5.5%
5Y26.0%10Y26.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.9%-101.2%+114.1%
TTM20.5%-211.9%+232.4%
YOY26.3%-209.8%+236.1%
5Y26.0%-342.2%+368.2%
10Y26.0%-488.9%+514.9%
4.3.1.2. Return on Assets

Shows how efficient Gempharmatech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Gempharmatech to the Biotechnology industry mean.
  • 0.9% Return on Assets means that Gempharmatech generated ¥0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.9%TTM1.4%-0.5%
TTM1.4%YOY1.6%-0.3%
TTM1.4%5Y1.8%-0.4%
5Y1.8%10Y1.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9%-12.3%+13.2%
TTM1.4%-12.3%+13.7%
YOY1.6%-11.8%+13.4%
5Y1.8%-13.3%+15.1%
10Y1.8%-15.3%+17.1%
4.3.1.3. Return on Equity

Shows how efficient Gempharmatech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Gempharmatech to the Biotechnology industry mean.
  • 1.0% Return on Equity means Gempharmatech generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 1.0%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.0%TTM1.6%-0.6%
TTM1.6%YOY1.9%-0.3%
TTM1.6%5Y2.1%-0.4%
5Y2.1%10Y2.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0%-15.8%+16.8%
TTM1.6%-16.9%+18.5%
YOY1.9%-15.2%+17.1%
5Y2.1%-19.5%+21.6%
10Y2.1%-20.7%+22.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Gempharmatech Co. Ltd. A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Gempharmatech is operating .

  • Measures how much profit Gempharmatech makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Gempharmatech to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.5%+201.5%
TTM--316.3%+316.3%
YOY--217.2%+217.2%
5Y--367.6%+367.6%
10Y--489.8%+489.8%
4.3.2.2. Operating Ratio

Measures how efficient Gempharmatech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.23 means that the operating costs are ¥1.23 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 1.232. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.144. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.232TTM1.144+0.088
TTM1.144YOY1.041+0.104
TTM1.1445Y1.044+0.100
5Y1.04410Y1.0440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2322.160-0.928
TTM1.1443.220-2.076
YOY1.0413.247-2.206
5Y1.0444.740-3.696
10Y1.0446.440-5.396
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Gempharmatech Co. Ltd. A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Gempharmatech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.91 means the company has ¥4.91 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 4.914. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.591. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.914TTM4.591+0.324
TTM4.591YOY6.233-1.642
TTM4.5915Y5.618-1.027
5Y5.61810Y5.6180.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.9143.610+1.304
TTM4.5913.865+0.726
YOY6.2334.596+1.637
5Y5.6185.968-0.350
10Y5.6186.183-0.565
4.4.3.2. Quick Ratio

Measures if Gempharmatech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Gempharmatech to the Biotechnology industry mean.
  • A Quick Ratio of 2.76 means the company can pay off ¥2.76 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 2.763. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.405. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.763TTM2.405+0.358
TTM2.405YOY3.697-1.292
TTM2.4055Y3.343-0.938
5Y3.34310Y3.3430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7633.035-0.272
TTM2.4053.357-0.952
YOY3.6974.345-0.648
5Y3.3435.954-2.611
10Y3.3436.490-3.147
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Gempharmatech Co. Ltd. A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Gempharmatech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Gempharmatech to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Gempharmatech assets are financed with 16.2% credit (debt) and the remaining percentage (100% - 16.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 0.162. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.174. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.162TTM0.174-0.012
TTM0.174YOY0.141+0.033
TTM0.1745Y0.157+0.017
5Y0.15710Y0.1570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1620.341-0.179
TTM0.1740.343-0.169
YOY0.1410.316-0.175
5Y0.1570.364-0.207
10Y0.1570.384-0.227
4.5.4.2. Debt to Equity Ratio

Measures if Gempharmatech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Gempharmatech to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.3% means that company has ¥0.19 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Gempharmatech Co. Ltd. A:

  • The MRQ is 0.193. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.211. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.193TTM0.211-0.018
TTM0.211YOY0.165+0.046
TTM0.2115Y0.188+0.023
5Y0.18810Y0.1880.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1930.385-0.192
TTM0.2110.428-0.217
YOY0.1650.391-0.226
5Y0.1880.450-0.262
10Y0.1880.492-0.304
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Gempharmatech generates.

  • Above 15 is considered overpriced but always compare Gempharmatech to the Biotechnology industry mean.
  • A PE ratio of 69.30 means the investor is paying ¥69.30 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Gempharmatech Co. Ltd. A:

  • The EOD is 65.361. Based on the earnings, the company is expensive. -2
  • The MRQ is 69.296. Based on the earnings, the company is expensive. -2
  • The TTM is 46.624. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD65.361MRQ69.296-3.936
MRQ69.296TTM46.624+22.672
TTM46.624YOY58.673-12.049
TTM46.6245Y49.644-3.020
5Y49.64410Y49.6440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD65.361-2.274+67.635
MRQ69.296-2.779+72.075
TTM46.624-3.256+49.880
YOY58.673-3.350+62.023
5Y49.644-6.153+55.797
10Y49.644-6.762+56.406
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Gempharmatech Co. Ltd. A:

  • The EOD is 141.097. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 149.594. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 106.817. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD141.097MRQ149.594-8.496
MRQ149.594TTM106.817+42.777
TTM106.817YOY-83.322+190.139
TTM106.8175Y14.653+92.164
5Y14.65310Y14.6530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD141.097-3.040+144.137
MRQ149.594-3.606+153.200
TTM106.817-3.837+110.654
YOY-83.322-4.520-78.802
5Y14.653-8.200+22.853
10Y14.653-9.265+23.918
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Gempharmatech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.86 means the investor is paying ¥2.86 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Gempharmatech Co. Ltd. A:

  • The EOD is 2.694. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.856. Based on the equity, the company is underpriced. +1
  • The TTM is 2.800. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.694MRQ2.856-0.162
MRQ2.856TTM2.800+0.056
TTM2.800YOY4.310-1.509
TTM2.8005Y3.740-0.940
5Y3.74010Y3.7400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6941.905+0.789
MRQ2.8562.242+0.614
TTM2.8002.437+0.363
YOY4.3102.470+1.840
5Y3.7403.744-0.004
10Y3.7404.444-0.704
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,533,540
Total Liabilities410,226
Total Stockholder Equity2,123,314
 As reported
Total Liabilities 410,226
Total Stockholder Equity+ 2,123,314
Total Assets = 2,533,540

Assets

Total Assets2,533,540
Total Current Assets1,677,727
Long-term Assets855,814
Total Current Assets
Cash And Cash Equivalents 490,780
Short-term Investments 567,252
Net Receivables 375,995
Inventory 57,944
Other Current Assets 169,388
Total Current Assets  (as reported)1,677,727
Total Current Assets  (calculated)1,661,359
+/- 16,367
Long-term Assets
Property Plant Equipment 621,004
Intangible Assets 56,850
Long-term Assets Other 3,201
Long-term Assets  (as reported)855,814
Long-term Assets  (calculated)681,055
+/- 174,759

Liabilities & Shareholders' Equity

Total Current Liabilities341,385
Long-term Liabilities68,841
Total Stockholder Equity2,123,314
Total Current Liabilities
Short Long Term Debt 68,089
Accounts payable 89,653
Total Current Liabilities  (as reported)341,385
Total Current Liabilities  (calculated)157,741
+/- 183,644
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt35,819
Long-term Liabilities  (as reported)68,841
Long-term Liabilities  (calculated)35,819
+/- 33,023
Total Stockholder Equity
Retained Earnings 432,455
Total Stockholder Equity (as reported)2,123,314
Total Stockholder Equity (calculated)432,455
+/- 1,690,859
Other
Capital Stock410,000
Common Stock Shares Outstanding 410,000
Net Invested Capital 2,191,403
Net Working Capital 1,336,342
Property Plant and Equipment Gross 621,004



6.2. Balance Sheets Structured

Currency in CNY. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
> Total Assets 
1,047,197
2,176,020
2,198,953
2,253,695
2,323,892
2,400,298
2,478,091
2,577,590
2,559,431
2,614,187
2,533,540
2,533,5402,614,1872,559,4312,577,5902,478,0912,400,2982,323,8922,253,6952,198,9532,176,0201,047,197
   > Total Current Assets 
672,194
1,562,487
1,437,576
1,467,010
1,510,222
1,599,839
1,627,276
1,657,523
1,648,108
1,744,108
1,677,727
1,677,7271,744,1081,648,1081,657,5231,627,2761,599,8391,510,2221,467,0101,437,5761,562,487672,194
       Cash And Cash Equivalents 
183,906
412,932
355,857
421,708
447,186
589,854
661,697
560,166
561,771
770,435
490,780
490,780770,435561,771560,166661,697589,854447,186421,708355,857412,932183,906
       Short-term Investments 
238,824
867,569
829,054
791,238
743,847
621,428
526,875
637,724
566,222
402,347
567,252
567,252402,347566,222637,724526,875621,428743,847791,238829,054867,569238,824
       Net Receivables 
153,866
186,490
190,355
185,216
222,069
245,987
281,444
269,390
319,024
358,483
375,995
375,995358,483319,024269,390281,444245,987222,069185,216190,355186,490153,866
       Inventory 
36,834
40,980
46,586
49,471
49,894
48,232
52,353
47,092
54,368
53,554
57,944
57,94453,55454,36847,09252,35348,23249,89449,47146,58640,98036,834
       Other Current Assets 
17,686
11,291
10,181
12,721
36,869
82,662
92,226
133,144
134,897
147,825
169,388
169,388147,825134,897133,14492,22682,66236,86912,72110,18111,29117,686
   > Long-term Assets 
375,003
613,533
761,377
786,684
813,670
800,459
850,815
920,067
911,324
870,079
855,814
855,814870,079911,324920,067850,815800,459813,670786,684761,377613,533375,003
       Property Plant Equipment 
0
0
0
0
427,195
466,323
505,307
618,920
636,728
627,162
621,004
621,004627,162636,728618,920505,307466,323427,1950000
       Intangible Assets 
49,753
49,226
48,628
48,514
48,273
47,361
47,467
47,341
47,827
54,572
56,850
56,85054,57247,82747,34147,46747,36148,27348,51448,62849,22649,753
       Long-term Assets Other 
5,157
199,146
290,984
258,172
230,202
178,505
186,943
109,598
75,972
25,976
3,201
3,20125,97675,972109,598186,943178,505230,202258,172290,984199,1465,157
> Total Liabilities 
231,280
282,530
258,401
276,002
313,309
357,326
395,198
452,933
428,203
500,987
410,226
410,226500,987428,203452,933395,198357,326313,309276,002258,401282,530231,280
   > Total Current Liabilities 
166,354
212,884
201,840
214,070
221,243
268,362
307,639
366,409
340,773
426,644
341,385
341,385426,644340,773366,409307,639268,362221,243214,070201,840212,884166,354
       Short Long Term Debt 
1,100
1,094
1,074
14,818
37,638
53,566
77,041
76,157
85,154
108,109
68,089
68,089108,10985,15476,15777,04153,56637,63814,8181,0741,0941,100
       Accounts payable 
54,096
85,101
66,923
50,787
48,487
57,028
64,082
101,860
89,471
94,588
89,653
89,65394,58889,471101,86064,08257,02848,48750,78766,92385,10154,096
       Other Current Liabilities 
0
0
0
68
0
0
0
0
0
0
0
000000068000
   > Long-term Liabilities 
64,925
69,646
56,561
61,933
92,065
88,964
87,559
86,524
87,431
74,343
68,841
68,84174,34387,43186,52487,55988,96492,06561,93356,56169,64664,925
       Long term Debt 
3,006
1,003
0
0
0
0
0
0
0
0
0
0000000001,0033,006
       Capital Lease Obligations Min Short Term Debt
5,183
5,243
4,347
3,047
37,482
36,563
36,142
36,071
38,341
37,382
35,819
35,81937,38238,34136,07136,14236,56337,4823,0474,3475,2435,183
> Total Stockholder Equity
815,918
1,893,490
1,940,552
1,977,692
2,010,583
2,042,972
2,082,893
2,124,656
2,131,228
2,113,200
2,123,314
2,123,3142,113,2002,131,2282,124,6562,082,8932,042,9722,010,5831,977,6921,940,5521,893,490815,918
   Common Stock00000000000
   Retained Earnings 
159,257
211,478
257,969
280,965
312,015
341,724
381,869
411,851
441,331
422,832
432,455
432,455422,832441,331411,851381,869341,724312,015280,965257,969211,478159,257
   Capital Surplus 00000000000
   Treasury Stock00000000000
   Other Stockholders Equity 00000000000



6.3. Balance Sheets

Currency in CNY. All numbers in thousands.




6.4. Cash Flows

Currency in CNY. All numbers in thousands.




6.5. Income Statements

Currency in CNY. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in CNY. All numbers in thousands.

Gross Profit (+$)
totalRevenue622,187
Cost of Revenue-201,519
Gross Profit420,668420,668
 
Operating Income (+$)
Gross Profit420,668
Operating Expense-455,840
Operating Income166,346-35,173
 
Operating Expense (+$)
Research Development96,597
Selling General Administrative82,741
Selling And Marketing Expenses0
Operating Expense455,840179,338
 
Net Interest Income (+$)
Interest Income17,134
Interest Expense-2,762
Other Finance Cost-224
Net Interest Income14,148
 
Pretax Income (+$)
Operating Income166,346
Net Interest Income14,148
Other Non-Operating Income Expenses0
Income Before Tax (EBT)161,288166,346
EBIT - interestExpense = -2,762
158,914
161,676
Interest Expense2,762
Earnings Before Interest and Taxes (EBIT)0164,049
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax161,288
Tax Provision-2,374
Net Income From Continuing Ops158,914158,914
Net Income158,914
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-14,148
 

Technical Analysis of Gempharmatech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Gempharmatech. The general trend of Gempharmatech is BULLISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Gempharmatech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (71.4%) Bearish trend (-71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Gempharmatech Co. Ltd. A.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 15.32 < 15.35 < 16.16.

The bearish price targets are: 12.54 > 12.07 > 12.04.

Tweet this
Gempharmatech Co. Ltd. A Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Gempharmatech Co. Ltd. A. The current mas is .

The long score for the Moving Averages is 12/14.
The longshort score for the Moving Averages is 10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Gempharmatech Co. Ltd. A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Gempharmatech Co. Ltd. A. The current macd is 0.06428397.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Gempharmatech price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Gempharmatech. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Gempharmatech price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Gempharmatech Co. Ltd. A Daily Moving Average Convergence/Divergence (MACD) ChartGempharmatech Co. Ltd. A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Gempharmatech Co. Ltd. A. The current adx is 17.63.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Gempharmatech shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Gempharmatech Co. Ltd. A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Gempharmatech Co. Ltd. A. The current sar is 13.00.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Gempharmatech Co. Ltd. A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Gempharmatech Co. Ltd. A. The current rsi is 58.56. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Gempharmatech Co. Ltd. A Daily Relative Strength Index (RSI) ChartGempharmatech Co. Ltd. A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Gempharmatech Co. Ltd. A. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Gempharmatech price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Gempharmatech Co. Ltd. A Daily Stochastic Oscillator ChartGempharmatech Co. Ltd. A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Gempharmatech Co. Ltd. A. The current cci is 124.38.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Gempharmatech Co. Ltd. A Daily Commodity Channel Index (CCI) ChartGempharmatech Co. Ltd. A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Gempharmatech Co. Ltd. A. The current cmo is 25.84.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Gempharmatech Co. Ltd. A Daily Chande Momentum Oscillator (CMO) ChartGempharmatech Co. Ltd. A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Gempharmatech Co. Ltd. A. The current willr is -16.4021164.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Gempharmatech Co. Ltd. A Daily Williams %R ChartGempharmatech Co. Ltd. A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Gempharmatech Co. Ltd. A.

Gempharmatech Co. Ltd. A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Gempharmatech Co. Ltd. A. The current atr is 0.51443692.

Gempharmatech Co. Ltd. A Daily Average True Range (ATR) ChartGempharmatech Co. Ltd. A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Gempharmatech Co. Ltd. A. The current obv is -46,692,422.

Gempharmatech Co. Ltd. A Daily On-Balance Volume (OBV) ChartGempharmatech Co. Ltd. A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Gempharmatech Co. Ltd. A. The current mfi is 69.53.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Gempharmatech Co. Ltd. A Daily Money Flow Index (MFI) ChartGempharmatech Co. Ltd. A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Gempharmatech Co. Ltd. A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Gempharmatech Co. Ltd. A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Gempharmatech Co. Ltd. A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.563
Ma 20Greater thanMa 5013.066
Ma 50Greater thanMa 10013.519
Ma 100Greater thanMa 20013.166
OpenGreater thanClose13.390
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Gempharmatech with someone you think should read this too:
  • Are you bullish or bearish on Gempharmatech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Gempharmatech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Gempharmatech Co. Ltd. A

I send you an email if I find something interesting about Gempharmatech Co. Ltd. A.


Comments

How you think about this?

Leave a comment

Stay informed about Gempharmatech Co. Ltd. A.

Receive notifications about Gempharmatech Co. Ltd. A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.